Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3

• US 8,541,376 B2
• Filed: 05/28/2008
• Issued: 09/24/2013
• Est. Priority Date: 11/16/2001
• Status: Active Grant

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Ferrara, Napoleone, Gerber, Hans-Peter, Kowalski, Joe, Pisabarro, Maria Teresa, Sherman, Daniel Eric
• Primary Examiner(s): Shafer, Shulamith H
• Application Number:
  US12/128,545
• Publication Number:
  US 20090098117A1
• Time in Patent Office: 1,945 Days
• Field of Search: None
• US Class Current: 514/21.2
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/515 Angiogenesic factors; Angiogenin
• CPC Class Codes: C12N 2799/022 where the vector is derived from an adenovirus

Abstract

The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.

Claims

1. A method for the treatment of acute liver disease, comprising administering to a mammalian subject in need by acute mode a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 98% sequence identity to the human Angptl3 sequence of SEQ ID NO:

2, or an agonist antibody of the polypeptide.

2. The method of claim 1 wherein the mammalian subject is human.

3. The method of claim 2 wherein said polypeptide comprises amino acid regions 281-293 (P1, SEQ ID NO:

14), 442-460 (P2, SEQ ID NO;

     15), and 415-430 (P3, SEQ ID NO;

     17) of the human Angptl3 sequence of SEQ ID NO;

2.

4. The method of claim 2 wherein said polypeptide comprises SEQ ID NO:

28.

5. The method of claim 2 further comprising the administration of an additional therapeutic agent.

6. The method of claim 5 wherein said additional therapeutic agent is an angiogenic factor.

7. The method of claim 6 wherein said angiogenic factor is vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF).

8. (Withdrawn/previously presented):

The method of claim 2 wherein said agonist antibody is an agonist antibody specifically binding Angptl3.